CTLA4 and head and neck squamous cell carcinoma: Moreover, mouse HNSCC lesions treated with in situ anti-CTLA4 showed similar immune infiltration and response rates than those induced by anti-PD-1 treatment in human HNSCC, so it could be used to identify response biomarkers that are relevant for patients [72].